Federal Trade Commission Deputy director of the Bureau of Competition Rahul Rao said the regulatory group’s tougher stance on pharmaceutical deals stems from a general view that market incentives in the sector had grown misaligned with competitive practices.
Key Takeaways
-
FTC deputy director of the Bureau of Competition Rahul Rao discussed some of the agency’s recent actions on pharma deals.
“There wasn’t a seismic event that happened,” he said. “What we are seeing is greater consolidation. We’re seeing the effects...